Humana Inc (HUM)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $54.05B
Last updated: Nov 17, 2026 at 11:06 AM ET
Humana Inc (HUM) Stock Forecast
Analysts expect Humana (HUM) to earn $9.52 per share in the fiscal year ending Dec 31, 2026, on revenue of $162.91B. Of 26 analysts, 16 rate the stock Buy or Strong Buy, 9 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 6 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 26 ratings average 2.31, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 62% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 11.5% |
| Buy | 13 | 50.0% |
| Hold | 9 | 34.6% |
| Sell | 1 | 3.8% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 26
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 89.9% and revenue estimates rise 6.5%.
- Fiscal year ending Dec 31, 2026
- $9.52
- EPS consensus, revenue $162.91B
- Fiscal year ending Dec 31, 2027
- $18.08
- EPS consensus, revenue $173.57B
- Next report
- Feb 9, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $9.52 | $9.05 to $10.43 | 23 | $162.91B | $162.00B to $164.24B | 17 |
| Dec 31, 2027 | $18.08 | $13.34 to $23.40 | 25 | $173.57B | $162.56B to $183.10B | 21 |
Quarterly Estimates
The EPS consensus rises from -$7.60 for the quarter ending Dec 31, 2026 to $13.15 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$7.60 | -$7.68 to -$6.94 | 27 | $41.98B | $40.05B to $46.75B | 21 |
| Mar 31, 2027 | $13.15 | $11.21 to $15.60 | 15 | $42.99B | $41.13B to $44.94B | 10 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 17 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 6 | 1 |
| Fiscal year ending Dec 31, 2027 | 7 | 0 |
| Quarter ending Mar 31, 2027 | 4 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.0% from $9.15.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $9.52 | $9.16 | $9.16 | $9.15 | $9.15 | +4.0% |
| Fiscal year ending Dec 31, 2027 | $18.08 | $17.09 | $17.09 | $16.57 | $16.57 | +9.1% |
| Quarter ending Mar 31, 2027 | $13.15 | $12.33 | $12.33 | $12.21 | $12.24 | +7.5% |
Frequently Asked Questions About HUM
What is the HUM stock forecast?
Consensus analyst estimates put Humana's EPS at $9.52 for the fiscal year ending Dec 31, 2026, on revenue of $162.91B. The consensus rating from 26 analysts is Buy.
How do analysts rate HUM stock?
Of 26 analysts covering Humana, 3 rate it Strong Buy, 13 Buy, 9 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from HUM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $9.52, with estimates from $9.05 to $10.43 from 23 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $18.08, with estimates from $13.34 to $23.40 from 25 analysts.
What revenue do analysts expect from Humana next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $162.91B, with estimates from $162.00B to $164.24B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $173.57B, with estimates from $162.56B to $183.10B.
How many analysts cover HUM?
26 analysts rate Humana stock, and 23 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
HUM pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors